Better tools are sorely needed for both the prevention and treatment of cardiovascular diseases, which account for more than one-third of the deaths in Western countries. MicroRNAs typically regulate the expression of several mRNAs involved in the same biological process. Therapeutic manipulation of miRNAs could restore the expression of multiple players within the same physiologic pathway, and ideally offer better curative outcomes than conventional approaches that target only one single player within the pathway. This review summarizes available studies on the prospective value of targeting miRNAs to prevent dyslipidemia and atherogenesis.
INTRODUCTION
MicroRNAs (miRNA) are $22 nt RNAs that associate to the RNA-Induced Silencing Complex (RISC) and bind to complementary sequences (generally in the 3 0 UTR) of target mRNAs, resulting in RNA degradation and/or translational repression of the target gene [1] . In the last decade, miRNAs have been recognized as essential regulators of multiple (patho)-physiological processes. Atherosclerosis is a progressive disorder of the vascular wall, which can result in plaques containing extracellular lipid, a necrotic core, and inflammatory cells [2, 3] . Such plaques can eventually rupture leading to heart attacks, strokes, and peripheral artery disease, which collectively accounted for more than 30% of all deaths in the USA during the last decade [4] . Dysregulation of lipid metabolism, especially hypercholesterolemia, has long been recognized as a risk factor for the both atherosclerosis and the risk of cardiovascular disease [4, 5] . Statins are the most common pharmacologic avenue for hypercholesterolemic patients [6, 7] . The potential for miRNA-based therapies (alone or in combination with statins) has been recently proposed as an alternative for patients at risk of developing cardiovascular disease. This review summarizes recent studies on antimiRNA-based therapies that exploit the ability of miRNAs to target key genes involved in hepatic and peripheral lipoprotein metabolism, with an emphasis on those miRNAs that influence both lipoprotein metabolism and atherosclerosis.
THE ROLE OF miR-33 ON REVERSE CHOLESTEROL TRANSPORT AND ATHEROGENESIS
SREBPs are the master regulators of sterol and fatty acid synthesis [8] . The miR-33 family consists of two members, miR-33a and miR-33b, expressed from within introns of SREBP-2 and SREBP-1, respectively [9] [10] [11] [12] [13] . The host and its intragenic miRNA are co-expressed, so conditions that modulate the expression of the SREBP genes result in concomitant changes in miR-33 levels [9] [10] [11] . Both miR-33 isotypes share the same seed sequence, but differ in 2 nt in the 3 0 region. Whether these 2 nt confer target specificity is currently unknown.
The relevance of miR-33 on sterol metabolism was initially revealed in studies showing that miR-33 modulated the expression of the cholesterol transporters ATP-binding cassette transporter A1 (ABCA1) and ABCG1, both in hepatocytes and macrophages [9] [10] [11] [12] [13] . Overexpression of miR-33 in the mouse liver resulted in attenuated expression of ABCA1 and ABCG1, and led to a concomitant decrease in plasma HDL cholesterol (HDL-C) [9] [10] [11] [12] . Conversely, antisense oligonucleotides (ASOs) that reduced miR-33 expression (ASO-33) resulted in increased hepatic amounts of these transporters, as well as elevated plasma HDL-C [9] [10] [11] . The phenotype of miR-33 À/À mice recapitulated the results with ASOs, with increased liver ABCA1 expression and elevated plasma HDL-C [13] . Hepatic bile secretion is also regulated by miR-33, via modulation of the canalicular transporters ABCB11 and ATP8B1 [14] . It was proposed that by controlling hepatic (and presumably also intestinal) HDL biogenesis (via ABCA1), peripheral HDL lipidation (via ABCA1 and ABCG1), and bile secretion (via ABCB11 and ATP8B1), miR-33 could modulate the flow of cholesterol through the reverse cholesterol transport (RCT) pathway [14, 15] . Importantly, studies in African green monkeys showed that the effect of ASO-33 on HDL-C was preserved in monkeys fed a variety of diets [16, 17] . Further studies in cells and in mice showed that miR-33 also coordinates the expression of genes involved in fatty acid b-oxidation and insulin signaling [12, 18, 19] . Collectively, these reports suggested that miR-33 is a regulatory hub for several intracellular metabolic processes. The data also implied that ASOs against miR-33 could be used therapeutically to raise HDL-C in patients and provide atheroprotection.
Further support for the proposal that miR-33 might be targeted to decrease cardiovascular risk came from population studies showing that the levels of miR-33a and/or miR-33b were increased in human atherosclerotic plaques, compared with normal artery walls [20 & ,21] and in the blood of hypercholesterolemic children, compared with healthy controls [22] . One should keep in mind, though, the small number of patients involved in these latter studies, and the very low levels of miR-33 in the circulation. Larger population studies will be necessary to firmly establish miR-33a/b as a bona fide biomarker of cardiovascular risk.
The consequences of loss of miR-33 on atherogenesis have been evaluated in several studies ( Table 1 ). The first study in Ldlr À/À mice showed that a 4-week treatment with 2 0 -fluoro/methoxyethyl (2 0 F/MOE) ASO-33 after 14-weeks of Western-type diet feeding raised HDL-C in circulation and accelerated the regression of atheromata, compared with control ASOs [15] . Another study in Western-type diet-fed Ldlr À/À mice using locked nucleic acid (LNA) ASOs showed that ASO-33 therapy did not sustain elevated plasma HDL-C levels over the course of 12 weeks, raised plasma triglycerides, and did not have an effect on the progression of atherosclerosis [23] . Three additional progression studies using 2 0 F/MOE ASO-33 in Western-type diet-fed Ldlr À/À mice [24,25 & ] and in ApoE À/À mice [20 & ] reported unchanged plasma HDL-C and yet a decrease in atheromata. Paradoxically, although HDL-C remained unchanged in these four progression studies, hepatic and/or macrophage Abca1 expression was still de-repressed in ASO-33-treated mice, compared with control ASOs. Perhaps the ASO-33-dependent atheroprotection in the context of unchanged HDL-C [20 & , 24, 25 & ] may be the result of direct effects of the ASO in the plaque: either through accelerated ABCA1/ABCG1-dependent cholesterol efflux to HDL, or decreased inflammatory burden. Authors
KEY POINTS
miRNAs that control the expression of key players of lipoprotein metabolism in liver and/or plaque might be exploited as therapeutic tools in patients at risk of cardiovascular disease. Some studies, especially those targeting miR-33, suggest that antimiRNA therapies might be useful to modulate the flow of cholesterol through the reverse cholesterol pathway, and attenuate atherogenesis.
The data on short-term vs. long-term effects of antimiR-33 therapy on cholesterol and triglyceride lipoproteins are inconsistent among different laboratories.
Further studies are necessary to establish definitive proof of the long-term efficacy (i.e., improved lipoprotein profiles and reduced atheromata) and safety of miRNA-based therapies.
showed that ASO-33 efficiently transduced macrophages in the aortic root of Ldlr À/À mice, and promoted the recruitment of M2 macrophages [15,25 & ] and T reg cells [25 & ]. These results suggest that anti-miR-33 therapy might exert its atheroprotective effects by promoting an anti-inflammatory phenotype directly in the plaque. Despite the low HDL-C levels and impaired cholesterol efflux previously demonstrated in ApoE À/À mice, transplantation with ApoE À/À Â miR-33 À/À bone marrow showed a significant reduction in lipid content within atherosclerotic plaques compared with mice transplanted with ApoE À/À , but no difference in circulating HDL-C or total plaque size [26] . Conversely, ApoE À/À Â miR-33 À/À mice had decreased atherosclerotic lesions, elevated plasma HDL-C, and decreased circulating monocytes, compared with ApoE À/À mice [26] . Hence, the relative contributions of hepatic and plaque miR-33 to atheroprotection are still unknown and require further investigation.
A few recent reports have shown that chronic antimiR-33 therapy might have unwanted effects that include hypertriglyceridemia [23, 27, 28] and hepatic steatosis [28] . Consistent with these latter observations, miR-33 -/mice gained weight at an accelerated pace and developed obesity, hepatosteatosis, and insulin resistance [29] . In contrast, other similar ASO long-term studies in mice and nonhuman primates showed no change [17, [24] [25] [26] or even a decrease [16, 30] in plasma TAG. The factors that explain the discrepancies in circulating lipids and atherogenesis among these studies are yet to be revealed.
In conclusion, despite the early promising results of ASO-33 in short-term experiments (elevated HDL-C and enhanced RCT), more recent longterm studies have introduced more questions than answers. Although some, but not all, studies suggest that antimiR-33 therapy might offer atheroprotection, the potential risk for obesity, hypertriglyceridemia, and fatty liver disease cannot be overstated. Finally, a critical aspect in miR-33-related studies in mice is that the intron of SREBP-1 containing miR-33b is altered in rodents, thus abrogating miR-33b expression. Given that the SREBP-2 and SREBP-1 genes are controlled by different nutritional and hormonal stimuli, murine studies are neglecting regulatory circuits controlled by miR-33b in the human liver, particularly in response to insulin. A miR-33b humanized transgenic mouse was recently reported [31] , which will presumably provide a better model to study the role of human miR-33a/b in physiology and disease. Additional studies will be necessary to establish the viability of ASO-33-based therapies in patients.
OTHER miRNAs THAT REGULATES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL METABOLISM
In addition to miR-33, a number of other miRNAs have been shown to control numerous aspects of 
A. green monkey ASO " # n.d. [16] A. green monkey ASO 38, 39] . Because of space limitation, we discuss only the recent findings of those miRNAs that influence both, HDL-C metabolism and atherosclerosis. Two independent reports have identified miR-144 as a regulator of ABCA1 expression in monocyte/macrophages and liver [32, 35] . The in-vivo experiments in both reports demonstrated that overexpression and inhibition of miR-144 decreases and increases circulating HDL-C respectively. These results were further confirmed by a third study, that also demonstrated that systemic miR-144 overexpression diminishes hepatic ABCA1 expression, decreases plasma HDL-C levels and enhances atherogenesis [40] . In addition to miR-144, miR-302a also controls the expression of ABCA1 and its expression influences HDL-C levels and the progression of atherosclerosis. Antagonism miR-302a in vivo increases hepatic ABCA1 and plasma HDL-C and attenuates atherosclerosis [41 & ].
THE ROLE OF miR-122 AND miR-30c IN VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL METABOLISM
A number of recent studies have reported the importance of miRNAs in controlling circulating LDL-C levels by regulating VLDL secretion, cholesterol biosynthesis and LDLR activity. The liver-enriched miR-122 was the first miRNA shown to control plasma LDL-C levels [42, 43] . Antagonism miR-122 using ASOs markedly reduces circulating LDL-C in rodents and nonhuman primates [42, 43] . Similarly, genetic ablation of miR-122 in mice results in a significant decrease in plasma total cholesterol (TC) and TAG [44] . Even though numerous groups have demonstrated the hypolipemic effect of miR-122 on TC levels, the molecular mechanisms by which miR-122 controls lipid metabolism remain poorly understood. Studies in miR-122 À/À mice and mice treated with miR-122 inhibitors have demonstrated that absence or inhibition of miR-122 results in a significant inhibition of lipid biosynthesis, enhanced fatty acid oxidation and reduced levels of hepatic microsomal triglyceride transfer protein (MTTP), an enzyme that plays a central role in lipoprotein assembly and VLDL production [42, 44, 45] . Despite these beneficial effects, studies in miR-122 deficient mice have shown that sustained loss of miR-122 in vivo result in hepatosteatosis, hepatitis, and hepatocellular carcinoma [42, 44, 45] . These observations damped the enthusiasm for developing antimiR-122 therapies for treating dyslipidemias.
In addition to miR-122, miR-30c also controls plasma LDL-C by regulating the expression of MTTP and numerous genes associated to hepatic lipid synthesis including lysophosphatidylglycerol acyl- 
IDENTIFICATION OF miR-148a AND OTHER miRNAs AS IMPORTANT REGULATORS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL METABOLISM AND ATHEROSCLEROSIS
Two recent studies have identified miRNAs that regulate circulating LDL-C using two different experimental approaches [33 && ,37 && ]. Interestingly, both studies uncovered the importance of miR-148a in regulating hepatic LDL receptor (LDLR) expression and activity. miR-148a is an intergenic miRNA encoded in chromosome 7 and highly expressed in the liver, adipose tissue and inflammatory cells (macrophages). Previous clinical data demonstrate an association with different SNPs in the miR-148a promoter region with altered plasma lipid (TC, LDL-C and triglyceride) levels [48, 49] . Although the mechanism by which these genetic variations within the promoter region of miR-148a influences circulating lipids is unknown, two independent laboratories have recently demonstrated that miR-148a levels affect the expression of LDLR and ABCA1 in human hepatic cells and in mouse liver [33 && ,37 && ]. Importantly, antagonism miR-148a in vivo markedly increased hepatic LDLR expression, lowering circulating LDL-C in two different mouse models (APOBTg;Ldlr À/þ and ApoE À/À ). Interestingly, miR-148a also regulates the expression of hepatic ABCA1 and inhibition of miR-148a increased plasma HDL-C levels in mice. These observations suggest that antagonism miR-148a might represent an interesting option to simultaneously lower plasma LDL-C and raise circulating HDL-C. In addition to regulating genes associated with lipid metabolism in the liver, miR-148a is also highly expressed in macrophages and its inhibition increases ABCA1 expression and enhances cholesterol efflux [37 && ], suggesting that miR-148a silencing might increase RCT, thereby attenuating atherogenesis. Further studies are necessary to determine whether absence of miR-148a or chronic miR-148a silencing influences the progression and regression of atherosclerosis.
In addition to miR-148a, other miRNAs that regulate LDLR expression have recently been identified, including miR-27a/b, miR-185, miR-128-1, miR-130b, and miR-301 [34,37 && ,50]. Of these miRNAs, only miR-128-1, miR-185 and miR-27a/b significantly altered plasma LDL-C in vivo. Most importantly, inhibition of miR-185 expression markedly reduces plasma TC and LDL-C levels and attenuates atherogenesis in ApoE deficient mice [50] . The results obtained using miR-27a/b mimics and inhibitors are somehow controversial. In the first study, the authors overexpressed and inhibited miR-27b using AAV8-miR-27b and LNA antimiR-27b respectively in C57BL6 mice [34] . The results showed that circulating HDL-C and LDL-C were not altered despite the significant effect of miR-27 levels on hepatic LDLR and ABCA1 expression [34] . In the second study, the authors assessed the effect of miR-27b overexpression and silencing in ApoE À/À mice [51] . Interestingly, the results showed that overexpression miR-27b increased plasma TAG levels, but decreased circulating TC and LDL-C. By contrast, antagonism miR-27b in ApoE À/À mice increased plasma TAG levels, but decreased circulating TC and LDL-C. These results were explained by the direct inhibitory effect of miR-27b in regulating lipoprotein lipase (LPL), a key enzyme that controls TAG hydrolysis from apoB-containing lipoproteins. However, whether or not miR-27b controls lipoprotein metabolism by inhibiting LPL expression and activity is not known. Thus, additional experiments assessing VLDL production and clearance are critical to support this notion. In addition to its role in controlling lipoprotein metabolism, miR-27b is highly expressed in macrophages and controls the expression of numerous mRNA targets associated with lipid metabolism including ABCA1, scavenger receptor A1, LOX-1, CD-36 and LPL [34, 52] . Nevertheless, the impact of miR-27b in regulating macrophage cholesterol metabolism and foam cell formation remains to be elucidated. These observations suggest that manipulating miR-27b in vivo could influence the progression of atherosclerosis. In fact, Xie et al. [51] have recently reported that overexpression and inhibition of miR-27b attenuates and enhances atherogenesis respectively in ApoE À/À mice.
TARGETING CARDIOVASCULAR RISK WITH ANTI-miRNAs
Evidence is accumulating that suggest a physiologic role for miRNAs in controlling different aspects of hepatic and peripheral lipid and lipoprotein metabolism, plaque growth and remodeling, inflammation, and other aspects of cardiovascular disease. Thus, considerable interest exists for the potential use of miR-based therapies to reduce cardiovascular risk. These strategies mostly involve loss-of-function approaches that abolish the function of a given miRNA. Several methods could be utilized to this end, that include: small-molecule inhibitors that interfere with miRNA expression or processing; miRNA-masking (miR-mask) using oligonucleotides complementary to the 3 0 -UTR of the target miRNA, resulting in the competitive inhibition of the endogenous mRNA:miRNA interaction; miRNA sponges containing multiple miRNA binding sites, which outcompete endogenous mRNA targets; and ASOs, also known as miRNA antagonists or antimiRNAs. All these oligonucleotides-based approaches require chemically modified backbones in order to resist degradation and improve pharmacokinetic properties. As noted in this review, antimiRNAs have been successfully used in several in vivo studies to knock-down the expression of specific miR-NAs, de-repress miRNA targets, and change a variety of physiologic parameters (i.e., plasma HDL or lesion size/composition).
A major roadblock of miRNA-based therapies is the potential of side-effects, given that miRNAs can target and alter the expression of many mRNAs. Thus, it is conceivable that ASO therapies that silence a particular miRNA will result in the de-repression of not only targets implicated in cardiovascular risk, but also many other targets that may or may not have beneficial effects. The challenge is to determine the right dosage of the antimiR ASOs to strike a balance between therapeutic and side-effects.
Finally, antimiRNAs are preferentially taken up by the liver and spleen (although de-repression of targets were also reported in other extra-hepatic tissues, including atheromata). Thus, miRNA-based therapies for dyslipidemias will be likely more successful when targeting hepatic lipid and biliary metabolism, and lipoprotein assembly and secretion, rather than peripheral lipoprotein clearance and metabolism. Whether new delivery systems (e.g. viral vectors or nanoparticle-based platforms) can be used to increase local delivery of antimiRNAs to the plaque needs further investigation. 
CONCLUSION
Recent studies have demonstrated the critical role of miRNAs in regulating lipid metabolism and related cardiovascular disorders. In particular, we have discussed in this review article how overexpression or inhibition of miRNAs influences circulating lipids and atherogenesis in mice and nonhuman primates. Despite these exciting findings, chronic treatment or genetic ablation of some of these miRNAs (miR-122 and miR-33) results in adverse effects including hepatic steatosis, dyslipidemia, obesity and hepatocellular carcinoma. As such, future experiments will be important for elucidating the molecular mechanisms by which miRNAs regulate lipid homeostasis. A combination of tissue specific knockout mouse models and cutting edge molecular biology techniques that allow the identification of miRNA target-selectivity in different tissues will help us to define the specific contribution of a single miRNA in controlling lipid metabolism. These steps are crucial if we want to translate these findings to the clinic.
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